RADIOTHERAPY-INDUCED ORAL TOXICITIES IN HIV-INFECTED ORAL AND OROPHARYNGEAL CANCER PATIENTS: A CASE CONTROL STUDY

• Published in: Oral surgery, oral medicine, oral pathology and oral radiology oral medicine, oral pathology and oral radiology, 2022-09, Vol.134 (3), p.e117-e117
• Main Authors: Prado-Ribeiro, Ana Carolina, De Oliveira, Leticia Rodrigues, De Oliveira, Maria Cecilia Querido, Migliorati, Cesar Augusto, Lopes, Marcio Ajudarte, Santos-Silva, Alan Roger, Brandão, Thaís Bianca
• Format: Article
• Language: English
• ISSN: 2212-4403; 2212-4411
• DOI: 10.1016/j.oooo.2022.01.199

Combined antiretroviral therapy led to improved survival rates among HIV patients, increasing the relevance of non-HIV related diseases such as oral and oropharyngeal squamous cell carcinoma (OSCC/OPSCC). The aim of the study was to evaluate the impact of acute oral toxicities in patients infected with HIV undergoing OSCC/OPSCC therapy. A retrospective case-control study conducted with patients with OSCC/OPSCC subjected to radiotherapy (RT) or chemoradiotherapy and allocated in 2 groups: HIV-infected (n = 17, case) and noninfected (n = 17, control). Oral toxicities were graded daily by a dentist. Patients from both groups were matched by sex, age, tumor site, clinical staging, and RT modality. Compared with non-HIV patients, patients with HIV presented similar acute oral toxicities, including oral mucositis (grade 2 [64.7% vs 58.82%] and grades 3/4 [35.3% vs 41.18%; P = .72]) xerostomia (grade 0 [11.76% vs 5.88%]; grade 1 [52.94% vs 70.59%]; and grade 2 [35.3% vs 23.53%; P = .76]); dysgeusia (grade 0 [0% vs 5.88%]; grade 1 [5.88% vs 5.88%]; and grade 2 [52.94% vs 64.71%; P = .70]); dysphagia (grade 1 [35.29% vs 52.94%]; grade 2 [35.29% vs 29.41%]; and grade 3 [11.77% vs 11.77%; P = .29]) and candidiasis (58.82% in both groups) outcomes. HIV status does not impact the clinical patterns of radiotherapy-induced acute oral toxicities among patients with OSCC/OPSCC.